Wells Fargo & Company MN Reduces Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Wells Fargo & Company MN trimmed its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 84.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,005 shares of the company's stock after selling 95,490 shares during the period. Wells Fargo & Company MN's holdings in Harmony Biosciences were worth $620,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Hillsdale Investment Management Inc. boosted its stake in Harmony Biosciences by 0.4% during the fourth quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company's stock valued at $2,340,000 after buying an additional 300 shares during the period. O Shaughnessy Asset Management LLC grew its holdings in shares of Harmony Biosciences by 2.1% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company's stock worth $704,000 after purchasing an additional 420 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after purchasing an additional 436 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock valued at $80,000 after purchasing an additional 519 shares in the last quarter. Finally, New York State Teachers Retirement System grew its stake in Harmony Biosciences by 2.6% in the 4th quarter. New York State Teachers Retirement System now owns 31,693 shares of the company's stock worth $1,091,000 after buying an additional 809 shares in the last quarter. 86.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on HRMY. HC Wainwright restated a "buy" rating and set a $70.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They set a "buy" rating and a $55.00 price target for the company. Mizuho increased their price objective on Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a research report on Tuesday, March 18th. UBS Group dropped their target price on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Monday, April 28th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $49.00 price target on shares of Harmony Biosciences in a research report on Tuesday. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Harmony Biosciences currently has a consensus rating of "Buy" and an average price target of $52.33.

Harmony Biosciences Trading Down 0.5 %

Shares of NASDAQ:HRMY traded down $0.16 during trading on Thursday, reaching $33.28. 62,111 shares of the company traded hands, compared to its average volume of 682,279. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 52-week low of $26.47 and a 52-week high of $41.61. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of 15.77, a P/E/G ratio of 0.47 and a beta of 0.82. The business's fifty day moving average is $31.31 and its 200-day moving average is $34.02.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $184.73 million during the quarter, compared to analysts' expectations of $184.26 million. During the same quarter in the prior year, the company posted $0.67 EPS. The firm's revenue for the quarter was up 19.5% compared to the same quarter last year. As a group, analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.